USE OF GONADOTROPIN-RELEASING-HORMONE AGONIST FOLLOWING FOLLICULAR ASPIRATION IN DONOR OOCYTE PROGRAM - IMPACT ON SUBSEQUENT MENSTRUATION

Objective-The present study evaluated the impact of continuous administration of gonadotropin-releasing hormone agonist (GnRH-a) following oocyte retrieval of oocyte donors in a donor oocyte program. Patients and Methods-Six patients from a donor oocyte program who underwent controlled ovarian hyperstimulation with midluteal GnRH-a and human menotropin had more than 20 mature ovarian follicles and serum estradiol levels greater than or equal to 3,000 pg/mL on the day of human chorionic gonadotropin administration. These patients resumed the use of GnRH-a immediately following follicular aspiration Three patients continued daily injection until the onset of next menses, while three took it irregularly, due to poor compliance. Results-Only one of the three patients who administered GnRH-a daily developed mild symptoms of ovarian hyperstimulation, and all resumed menstruation within 13 days following aspiration. All three patients who failed to comply, and used GnRH-a sporadically, developed symptoms of ovarian hyperstimulation and experienced delayed menstrual periods. One of these three patients required hospitalization. Conclusion-Our data suggest that continuous postaspiration GnRH-a use may be beneficial for oocyte donors whose ovaries are hyperstimulated. Sporadic administration of GnRH-a is not effective and may delay the resumption of spontaneous menstruation.